Enochian BioSciences Announces Scientific Presentation at World Vaccine Conference on Promising Human and Laboratory Data to Potentially Treat Solid Tumors
Enochian BioSciences, Inc. (NASDAQ: ENOB) announced a collaboration with Dr. Anahid Jewett to tackle pancreatic cancer, utilizing innovative genetic modifications in dendritic cells. Dr. Serhat Gumrukçu presented promising lab results that suggest potential efficacy in treating glioblastoma, highlighted by a case where a patient remained tumor-free for two years post-treatment. The company aims to progress from laboratory results to animal models and eventually human trials. CEO Dr. Mark Dybul expressed enthusiasm about this breakthrough partnership and its implications for future cancer therapies.
- Collaboration with Dr. Anahid Jewett focuses on pancreatic cancer treatments.
- Promising laboratory data on genetic modifications in dendritic cells.
- Successful case report of a glioblastoma patient tumor-free for 2 years.
- None.
LOS ANGELES, Dec. 03, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) – Enochian BioSciences, Inc., a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today announced that Dr. Serhat Gumrukçu, Inventor and Co-Founder of Enochian BioSciences, and Founder and Director of Seraph Research Institute (SRI), presented new data and announced a partnership between Enochian and Dr. Anahid Jewett, a leader in tumor immunology and cell and gene therapy, on pancreatic cancer, as well as a combined effort with SRI and Enochian on Glioblastoma.
For the first time, Dr. Gumrukçu revealed the proprietary genetic modifications of allogeneic (from another person) dendritic cells (DC) that are the basis of Enochian’s oncology pipeline, and laboratory studies showing a strong response across key parts of the immune system.
He also provided an update on a published case report (link to release & report) of a patient with recurrent glioblastoma who had a remaining tumor after surgery to remove it, which carries a very poor prognosis. The patient was treated with non-genetically-modified allogeneic DC loaded with an antigen known to be part of many glioblastomas and allogeneic Natural Killer cells. At the time of the report, the patient was tumor free for 15 months. He is now 2 years without evidence of the cancer recurring. The laboratory data presented suggest the Enochian pipeline products could be even more effective.
“I am thrilled to be collaborating with Enochian BioSciences on an approach that could potentially be effective against pancreatic cancer, for which there is currently poor treatment options,” said Dr. Anahid Jewett. “The laboratory data are quite encouraging. I look forward to conducting experiments including those in the humanized mouse model I designed to study pancreatic cancer.”
Dr. Mark Dybul, the CEO of Enochian Bio said: “We are very excited about the promising data and the partnerships with Dr. Jewett, and SRI to move as quickly as possible to advance from in vitro laboratory data to animal models and, we hope, humans.”
The presentation can be found at: Presentation Link
About Enochian BioSciences, Inc.
Enochian BioSciences, Inc. is a biopharmaceutical company focused on developing innovative platforms for gene-modified cellular and immune therapies to potentially cure and treat deadly diseases. The company’s gene-modified cell and immune therapy platforms can potentially be applied to multiple indications, including HIV/AIDS, Hepatitis B, all SARS-CoV and Influenza viruses, and Oncology. For more information, please visit Enochianbio.com
Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties, including but not limited to the success or efficacy of our pipeline. All statements other than historical facts are forward-looking statements, which can be identified by the use of forward-looking terminology such as “believes,” “plans,” “expects,” “aims,” “intends,” “potential,” or similar expressions. Actual events or results may differ materially from those projected in any of such statements due to various uncertainties, including as set forth in Enochian BioScience’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Enochian BioSciences undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
FAQ
What recent partnership did Enochian BioSciences announce regarding pancreatic cancer?
What are the key findings from Enochian's recent research presentation?
How long has the glioblastoma patient remained tumor-free after Enochian's treatment?
What is the stock symbol for Enochian BioSciences?
What type of therapies does Enochian BioSciences focus on developing?
